Tagraxofusp

- Novel targeted therapy directed to CD123
- FDA-approved for the treatment of adult and pediatric patients, 2 years and older, with high-risk differentiated T-cell lymphoma (PTCL)
- Breakthrough Therapy Designation (BTD) designation
- Marketing Authorization Application (MAA) for SBPDC1 granted accelerated assessment and, under review, by the EMA

CD123 target

- Expressed by multiple malignancies, including certain myeloid/lymphoid neoplasms (MLNs) such as chronic myelomonocytic leukemia (CMML) and myelodysplasia (MF), acute common myeloid leukemia (AML) patient subsets, BPDCN and others

Tagraxofusp and CMML

Tagraxofusp has demonstrated clinical activity, with a predictable and manageable safety profile, in this Phase 2 trial (OCT2028523) of patients with relapsed/refractory CMML.

- Patient enrollment is ongoing
- Given the encouraging data from this trial and the unmet medical need in patients with CMML, a pivotal program is being constructed

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, Haris Ali, Abdullahreham Yacoubi, Vikas Gupta, Sangmin Lee, Eunice Wang, Gary Schiller, Megan Sardone, Halya Wysowsky, Shay Shemes, Janice Chen, Chris Brooks, Enrique Poradossi, Peter McDonald, Nicole Rupprechter, Animesh Pandarani, Ayahel Teffe, Minaschi Tapara, Moshe Talpa, Srdan Verstovsek, Joseph Khoury, Naveen Penner

1 Mayo Clinic, Rochester, City of Hope, Duarte, UMSOM, Baltimore, Maryland, USA, 2...